A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

• Main Authors: Lai, Gillianne GY, Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob JS, Sim, Ngak Leng, Tan, Aaron C, Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie PL, Rohatgi, Neha, Yeong, Joe PS, Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders MJ, Tan, Eng-Huat, Tan, Daniel SW
• Other Authors: DEPARTMENT OF COMPUTER SCIENCE
• Format: Article
• Language: English
• Published: ELSEVIER 2024
• Subjects: Science & Technology; Life Sciences & Biomedicine; Oncology; Respiratory System; Lung cancer; Epidermal growth factor receptor; Immunotherapy; Biomarkers; CELL LUNG-CANCER; TUMOR MUTATIONAL BURDEN; OPEN-LABEL; PLUS IPILIMUMAB; IMMUNE ESCAPE; DOCETAXEL; PD-L1; PEMBROLIZUMAB; BLOCKADE; ASSOCIATION
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/248899
• Institution: National University of Singapore

10.1016/j.jtocrr.2022.100416